Common use

Strattera is a leading non-stimulant ADHD medication containing atomoxetine HCl as its active ingredient. Unlike traditional stimulant-based treatments, Strattera works as a selective norepinephrine reuptake inhibitor (SNRI) that targets presynaptic norepinephrine transporters in the brain. This unique mechanism of action makes it an excellent choice for patients seeking ADHD treatment without the risks associated with stimulant medications. If you are considering buying Strattera online, understanding how atomoxetine improves focus and concentration is essential.

Attention deficit hyperactivity disorder (ADHD) affects both children and adults, presenting with symptoms that may include lack of concentration, persistent distractibility, excessive restlessness, impulsiveness, disorganization, difficulty completing tasks, and other behavioral challenges. These manifestations must typically be observed in more than one social environment — such as school, work, and home — for a clinical diagnosis. Strattera (atomoxetine) addresses these core symptoms by increasing norepinephrine levels in key brain regions responsible for attention, impulse control, and executive function. As a trusted focus medication, Strattera generic versions offer the same therapeutic benefits as the brand-name product, making effective ADHD medication accessible to more patients.



Dosage and direction

Take Strattera once or twice daily as prescribed, with or without food. Swallow the capsules whole — do not open, crush, or sprinkle the contents on food, as atomoxetine can irritate the eyes and mucous membranes upon direct contact.

The recommended initial dose for children, adolescents, and adults weighing over 70 kg is 40 mg per day. Your doctor should increase this to the therapeutic daily dose of 80 mg no earlier than three days after starting treatment. If attention deficit symptoms do not improve sufficiently, the maximum daily dose of Strattera may be increased to 120 mg — but not sooner than 2 to 4 weeks after beginning the medication.

For patients weighing less than 70 kg, the initial dose is typically 0.5 mg/kg per day, which may be increased to a target of 1.2 mg/kg per day. Always take atomoxetine exactly as prescribed by your healthcare provider. Do not adjust your dose without medical guidance.

If Strattera needs to be discontinued, gradual dose reduction is not required — however, consult your doctor before stopping this ADHD treatment to ensure the best management of your condition.



Precautions

Before you buy Strattera online or begin atomoxetine therapy, inform your doctor about your complete medical history. This is especially important if you have hypertension, tachycardia, cardiovascular or cerebrovascular circulation disorders, congenital heart defects, coronary artery disease, heart rhythm disorders, a recent heart attack, or any condition that may cause low blood pressure.

Notify your doctor if you have liver disease, problems with urination, bipolar disorder, any mental illness, psychotic disorder, depression, or a history of suicide attempts. Strattera carries a boxed warning regarding an increased risk of suicidal thinking in children and adolescents, so close monitoring during the initial weeks of ADHD treatment is essential.

The safety of atomoxetine during pregnancy has not been fully established. This focus medication should only be administered to pregnant women when the potential benefits clearly outweigh the possible risks. If you become pregnant while taking Strattera, contact your doctor immediately.

Patients with attention deficit disorders should have regular follow-up appointments to monitor the effectiveness of this non-stimulant medication and assess for any adverse effects on concentration and overall well-being.



Contraindications

Strattera (atomoxetine) is contraindicated in patients who are currently taking or have recently taken monoamine oxidase (MAO) inhibitors, including Pirlindole, Metralindol, Moclobemide, and Nialamide. A minimum washout period of 14 days must elapse after discontinuing MAO inhibitor therapy before starting Strattera. This ADHD medication is also contraindicated in individuals with narrow-angle (closure-angle) glaucoma, pheochromocytoma, severe cardiovascular disorders, and known hypersensitivity to atomoxetine or any component of the formulation.



Side effects

Common side effects of Strattera include allergic symptoms (hives, rash, facial swelling, edema), dry mouth, decreased appetite, nausea, stomach upset, vomiting, dizziness, fatigue, mood changes, difficulty falling asleep, urinary problems, and sexual side effects. These are generally mild and may improve as your body adjusts to the ADHD medication.

More serious side effects that require immediate medical attention include fast or irregular heartbeats, chest pain, shortness of breath, feeling light-headed or fainting, persistent low-grade fever, dark-colored urine, clay-colored stools, jaundice (yellowing of skin or eyes), significant increase in blood pressure, or decreased urination. Atomoxetine may also rarely cause serious liver injury — seek urgent care if you experience unexplained nausea, abdominal pain, or jaundice.

Report any unusual changes in mood, behavior, or concentration to your healthcare provider promptly. Buy atomoxetine only with a valid prescription and under proper medical supervision.



Drug interaction

Strattera must not be co-administered with MAO inhibitors. A minimum 14-day break between the last dose of any MAO inhibitor — such as Nardil (phenelzine) or Parnate (tranylcypromine) — and the first dose of atomoxetine is required to prevent potentially dangerous interactions.

Several medications may increase blood levels of Strattera by inhibiting the liver enzyme (CYP2D6) responsible for metabolizing atomoxetine. These include fluoxetine (Prozac), paroxetine (Paxil), bupropion (Wellbutrin, Zyban), quinidine, and other strong CYP2D6 inhibitors.

Inform your doctor about all medications and herbal products you use, including albuterol (Proventil, Ventolin), cimetidine (Tagamet), amiodarone (Cordarone, Pacerone), celecoxib (Celebrex), methadone, doxorubicin (Adriamycin), ranitidine (Zantac), terbinafine (Lamisil), metoclopramide (Reglan), and ritonavir (Norvir). Comprehensive drug interaction review is essential before starting this non-stimulant ADHD treatment.



Missed dose

If you forget to take your dose of Strattera, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take a double dose or extra doses of this focus medication. Resume your usual atomoxetine dose the next day at the regularly scheduled time to maintain consistent ADHD treatment.



Overdose

The majority of reported Strattera overdose cases have been moderate in severity. Symptoms may include tachycardia (rapid heartbeat), dry mouth, convulsions, hyperactivity, behavioral disturbances, drowsiness or agitation, stomach upset, mydriasis (excessive pupil dilation), blurred vision, and fast heartbeat. If you suspect an atomoxetine overdose, seek emergency medical attention immediately. Contact your local poison control center or emergency services without delay.



Storage

Store Strattera at room temperature between 68-77 degrees F (20-25 degrees C). Keep the medication away from moisture, heat, and direct sunlight. Do not store atomoxetine in the bathroom. Keep all ADHD medications out of reach of children and pets. Dispose of expired Strattera generic or brand-name capsules according to local pharmacy guidelines.



Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.